19 U.S.C. § 1337a
Repealed. Pub. L. 100–418, title I, § 1342(c), Aug. 23, 1988, 102 Stat. 1215
[repealed]
Notes of Decisions
Cited in 5
cases, 1986–2011 · leading case: TianRui Grp. Co. v. Int'l Trade Comm'n, 661 F.3d 1322 (Fed. Cir. 2011).
TianRui Grp. Co. v. Int'l Trade Comm'n, 661 F.3d 1322 (Fed. Cir. 2011). “19 U.S.C. § 1337a (1940); see S.Rep. No. 76-1903, at 1-2 (1940); H.”
Viscofan, S.A. v. U.S. Int'l Trade Comm'n, Union Carbide Corp., & Teepak, Inc., 787 F.2d 544 (Fed. Cir. 1986). “§ 1337 (1982), and 19 U.S.C. § 1337a (1982), and (2) the Commission’s refusal to declassify confidential information that had been submitted during the Commission proceedings pursuant to a protective order.”
Corning Glass Works v. United States Int'l Trade Comm'n, Sumitomo Elec. Indus., Ltd., Sumitomo Elec. U.S.A., Inc., Intervenors, 799 F.2d 1559 (Fed. Cir. 1986). “However, the activity is declared by 19 U.S.C. § 1337a to provide grounds for exclusion of imports made by the process.”
Eli Lilly & Co. v. Am. Cyanamid Co., & Biocraft Labs., Inc., & Zenith Labs., Inc., & Biochimica Opos, S.P.A., 82 F.3d 1568 (Fed. Cir. 1996). “In that setting, the process patent owner’s only legal recourse was to seek an exclusion order for such products from the *1572 International Trade Commission under section 387a of the Tariff Act of 1930, 19 U.S.C. § 1337a (1982). By enacting the Process Patent Amendments Act,…”
Amgen, Inc. v. United States Int'l Trade Comm'n, Chugai Pharm. Co., Ltd. & Chugai Pharma U.S.A., Inc., Intervenors, 902 F.2d 1532 (Fed. Cir. 1990). “§ 1337 ; See also 19 U.S.C. § 1337a by importing recombinant erythro-poietin (rEPO) made by a process covered by the ’008 patent.”
Annotations are extracted automatically from the opinions in the
Syfert caselaw corpus and ranked by authority, recency, and
treatment. Dots show Syfertize treatment of the citing case itself.